Apogee Therapeutics, Inc. (APGE)

NASDAQ

$76.82

-$0.26 (0.34%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$76.03$77.71

Open $77.71

52 Week Range

$26.20$78.15

Previous Close $77.08

Market Cap4.21B

Volume732.02K

Avg Volume787.17K

P/E (TTM)-17.88

EPS (TTM)$-4.32

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Apogee Therapeutics, Inc.

NOV102025

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Source: GlobeNewsWire•36 days ago

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD...

NOV102025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Source: GlobeNewsWire•36 days ago

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing...

NOV32025

Apogee Therapeutics to Participate in Upcoming Conferences

Source: GlobeNewsWire•43 days ago

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2 nd Annual Healthcare Innovation Con...

OCT102025

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Source: GlobeNewsWire•66 days ago

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory an...

OCT82025

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Source: GlobeNewsWire•68 days ago

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory an...

OCT82025

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Source: GlobeNewsWire•68 days ago